source
- Merck and Moderna’s personalized mRNA vaccine shows longer recurrence-free survival in phase 3 melanoma trialMerck and Moderna reported that their individualized mRNA cancer vaccine, given together with Keytruda, extended the time patients remained free of melanoma recurrence in a late-stage study. The p…
- Leo Pharma to license Tanabe’s oral drug for rare light-sensitive skin disease, paying up to $435 millionLeo Pharma announced a licensing agreement with Japan's Tanabe Pharma for an oral treatment targeting two genetic skin disorders that cause pain when exposed to sunlight. Under the deal, Leo Pharm…